Brown & Brown's 7.4% Growth Hides a 1.2% Organic Stall

Brown & Brown's third-quarter results looked stronger at the top line than they did underneath it. Total revenue rose 7.4% to $1.725 billion, but the company's organic revenue measure increased only 1.2%. TIKR reported that revenue missed the $1.76 billion analyst estimate and adjusted earnings of $1.07 a share missed by one cent, helping send the stock down about 5%.

Acquisitions did the heavy lifting

Brown & Brown's own reconciliation shows why the growth mix matters. Commissions and fees reached $1.7 billion, up from $1.55 billion a year earlier. Acquisitions contributed $156 million, while organic revenue was $1.464 billion, only $17 million above the comparable 2025 amount. Including contingent commissions, organic growth was 1.5%.

The pattern is even clearer over the first nine months of 2026. Total revenue increased 23.4% to $5.302 billion after the Accession acquisition entered the comparison, while organic revenue grew just 0.3%. Acquisitions contributed $985 million to the nine-month reconciliation. The company is growing, but most of that growth has come from purchased businesses rather than faster expansion in the existing book.

Profitability also carried an important comparison issue. Adjusted EBITDAC rose 1.7% to $597 million, but the adjusted margin fell to 34.6% from 36.6%. Brown & Brown said the 2025 quarter benefited from about $29 million of interest income earned on cash raised before the Accession deal closed. That prior-year benefit explains more than half of the two-percentage-point margin decline, but it does not erase the pressure from slower organic growth.

Reported net income attributable to Brown & Brown increased 5.7% to $240 million. Diluted reported earnings fell to $0.67 from $0.68, while adjusted diluted earnings rose 1.9% to $1.07. The difference reflects acquisition and integration costs, amortization and other adjustments, so investors should not treat the two earnings measures as interchangeable.

The 2027 test

The earnings call showed a split between Brown & Brown's two operating segments. Retail organic revenue grew 2.6%, while Specialty Distribution declined 0.8% excluding contingent commissions. Management pointed to pressure from admitted insurers, lower excess-and-surplus property pricing and delays in a lender-placed program.

For the fourth quarter, management expects Retail organic growth of 2% to 3%, excluding contingents, and a 2% to 4% decline in Specialty Distribution. The Specialty forecast includes $8 million to $12 million of nonrecurring and timing-related pressure. Preliminary 2027 ranges call for 2% to 4% organic growth in Retail and 1% to 3% in Specialty Distribution.

Accession gives Brown & Brown another lever. The company raised expected 2026 EBITDAC synergies to about $50 million from $30 million to $40 million, and lifted its expected run-rate synergies by the end of 2028 to $175 million from $150 million. The same presentation raised expected one-time integration costs to $250 million to $300 million, so the larger benefit does not come free.

Cash generation remains a counterweight to the slower organic trend. Operating cash flow increased 13% to $1.14 billion during the first nine months, and Brown & Brown spent $750 million on share repurchases. At September 30, the balance sheet separately listed $1.099 billion of cash and equivalents and $2.442 billion of fiduciary cash, which should not be combined as one pool of deployable corporate cash. Current and long-term debt totaled about $7.76 billion.

The investment question is whether Accession's cost savings and the expected rebound in Specialty can produce better organic growth without further margin pressure. Until that appears in reported results, the 7.4% revenue increase tells only part of the story.